Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV-SMENP Vaccine for Covid-19
NCT04276896Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LV-SMENP Vaccine in coronavirus disease 2019 (COVID-19), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoints: Clinical improvement based on the 7-point scale at 28 days and Lower Murray lung injury score at 7 days. Started Jun 2026; status: terminated.
02
Drugs
LV-SMENP Vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04276896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276896.